Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.

Cancer medicine - 1 Apr 2021

Chung Wei-Pang, Huang Wei-Lun, Liao Wei-An, Huang Wan-Ling, Liu You-Yu, Su Wu-Chou

Abstract excerpt

BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer who fail to respond to anti-HER2 treatments have poor prognoses. Most trastuzumab-resistant breast cancer cell lines available from biobanks feature either phosphoinositide-3-kinase, catalytic, alpha (PIK3CA) mutation or the loss of phosphatase and tensin homolog (PTEN). However, PIK3CA mutations and/or PTEN loss do...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Ascites

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Erb-b2 Receptor Tyrosine Kinases

Share to MCF-7 Cells

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 33665980
DOI: 10.1002/cam4.3824
PMCID: PMC7982635

Genes

MB
PIK3CA
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.PMID 33665980Read ↗

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.Semantic proximity Read ↗

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesSemantic proximity Read ↗

Breast cancer mutations HER2 <sup>V777L</sup> and PIK3CA <sup>H1047R</sup> activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistanceSemantic proximity Read ↗

Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing.Semantic proximity Read ↗

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseSemantic proximity Read ↗

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.Semantic proximity Read ↗

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast CancerSemantic proximity Read ↗

Concurrent Mutations Associated With Trastuzumab-resistance Revealed by Single Cell SequencingSemantic proximity Read ↗

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.Semantic proximity Read ↗

Therapeutic targeting of casein kinase 1δ in breast cancerSemantic proximity Read ↗

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.Semantic proximity Read ↗

Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.